Abstract
Salivary gland dysfunction (SGD) is a common problem in patients with advanced cancer, and is associated with significant morbidity in this group of patients. The management of SGD involves treatment of the cause, treatment of the symptoms (preferably with saliva stimulants), prevention of the complications, and treatment of the complications. This article reviews the evidence for the clinical utility of various management strategies, highlighting those strategies that have been investigated in patients with advanced cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
